SAB Biotherapeutics, Inc. - SABS STOCK NEWS

SAB Biotherapeutics announced positive top-line results from the Phase 3 NIH ACTIV-2 clinical trial evaluating SAB-185, a human IgG1 antibody therapeutic candidate, in non-hospitalized COVID-19 patients at high risk of severe outcomes. The trial found that 66% of participants receiving SAB-185 achieved full symptom resolution for at least four consecutive days by Day 28, compared to 50% for the REGEN-COV® group (p=0.010). Furthermore, the median time to symptom resolution was significantly shorter for SAB-185, with a reduction of 7 days for 4-day resolution and 6 days for 2-day resolution. However, the primary endpoint regarding hospitalizations and deaths was inconclusive due to the low number of clinical events following the emergence of the Omicron variant. The trial was halted based on recommendations from the Data and Safety Monitoring Board.

SAB Biotherapeutics announced that its investigational therapeutic, SAB-176, has received both Breakthrough Therapy and Fast Track designations from the FDA for treating high-risk patients and post-exposure prophylaxis of Type A and B influenza. This dual designation could significantly expedite its development and regulatory process. SAB-176, a fully-human multi-epitope binding antibody, shows promise against antiviral-resistant strains of influenza. The company is poised to initiate a Phase 2b trial after receiving FDA guidance, highlighting its clear regulatory pathway for further development. The therapy aims to offer broad protection against evolving influenza strains, potentially addressing significant health concerns globally.

SAB Biotherapeutics has announced the FDA granting Fast Track designation for SAB-176, an investigational immunotherapy for treating Type A and Type B influenza in high-risk patients. This therapeutic approach is significant as it produces fully-human antibodies without needing human donors, utilizing the proprietary DiversitAb™ platform. The FDA's approval facilitates the advancement into a Phase 2b trial to evaluate the safety and efficacy of SAB-176, particularly among patients with antiviral-resistant influenza strains. This innovative therapy aims to provide broad protection against rapidly mutating influenza viruses, responding to the global health challenges posed by seasonal and pandemic influenza.

SAB Biotherapeutics announced the appointment of Erick Lucera, CFA, to its Board of Directors, effective April 4, 2023. Lucera, with over 30 years of experience in the biotechnology and medical device sectors, previously served as CFO for AVEO Oncology. His extensive background includes leadership roles at various biotech firms where he oversaw financial strategies and helped raise significant capital. The Executive Chairman, Samuel J. Reich, expressed confidence in Lucera's abilities to guide SAB through significant milestones in its immunotherapy development programs targeting critical health issues like C. difficile and type 1 diabetes.

SAB Biotherapeutics reported its financial results for the year ended December 31, 2022, highlighting progress in its immunotherapy platform, which creates fully-human polyclonal antibodies without human donors. The company advanced its type 1 diabetes program and introduced SAB-195 for C. diff, while achieving positive results in its Influenza and SARS-CoV-2 therapeutic candidates. SAB's cash reserves declined to $15 million from $33.2 million in 2021, with reduced annual net cash consumption from $60 million to $18 million. The company will restate its 2021 financials due to an accounting error. Despite these challenges, SAB maintains its guidance to fund operations through December 2023.

SAB Biotherapeutics (NASDAQ: SABS) recently featured CEO Eddie Sullivan on Episode 67 of ICR's podcast, "Welcome to the Arena." The discussion highlighted SAB's innovative immunotherapy platform, which produces fully-human polyclonal antibodies without relying on human donors. Sullivan shared insights on their polyclonal antibody research, the application of cows in their processes, and the challenges facing the biotech industry. ICR's podcast, aimed at enhancing corporate communication, has been running since August 2021.

SAB Biotherapeutics (Nasdaq: SABS, SABSW) announced that its co-founder and CEO, Dr. Eddie Sullivan, will present at the 2023 BIO CEO & Investor Conference in New York City from February 6-9. The presentation will feature SAB's proprietary DiversitAb™ platform, which uniquely produces fully-human polyclonal antibodies without human donors. Dr. Sullivan emphasized the importance of developing therapies for viral infections like COVID-19 and influenza and highlighted progress in treating autoimmune disorders. Interested parties can schedule meetings through the BIO One-on-One Partnering system.

SAB Biotherapeutics (SABS) has received an additional $8.2 million from the U.S. Department of Defense, raising the total amount to $16.8 million since November 2022, related to the closeout of a discontinued COVID-19 contract. The contract was originally awarded in 2019 but was terminated in August 2022 due to misalignment with government requirements. CEO Eddie Sullivan noted that this funding validates SAB's antibody platform, which is moving to Phase 3 development for various medical programs, including Influenza and Type 1 Diabetes. The company expects sufficient cash flow to fund operations through 2023.

SAB Biotherapeutics (SABS) announced the successful completion of a GLP-tox study for SAB-142, its fully-human polyclonal therapeutic aimed at delaying type 1 diabetes onset. The study demonstrated SAB-142's well-tolerated profile at various doses and its pharmacodynamic effects compared to FDA-approved treatments. The company plans to file an IND within 12 months. SAB-142's development marks a significant milestone, potentially offering a safer treatment option for patients by reducing immune-related adverse reactions commonly seen with animal-derived therapies.